louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06784830: Nursing Interventions for Alzheimer's Patients During PET/CT Imaging
Official title: Enhancing Nursing Interventions for Alzheimer's Patients During PET/CT Imaging: Effects on Image Quality and Patient Satisfaction
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alzheimer's Disease
Lead sponsor: Sichuan Provincial People's Hospital
Sponsor class: OTHER
First posted: 2025-01-20
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The impact of nursing Interventions during PET/CT imaging in Alzheimer's patients on image quality and patient satisfaction will be assessed in 200 patients.

Detailed description: This study will analyze clinical data from 200 Alzheimer's disease (AD) patients who underwent PET imaging and were admitted to Sichuan Provincial People's Hospital over a period of six months. The control group will receive routine nursing intervention, while the observation group will receive a refined specialized nursing intervention. We will meticulously compare various performance aspects in both groups to assess the impact of refined specialized nursing intervention on patients' image quality and patient satisfaction.

Eligibility criteria: Inclusion Criteria:

* Meet the criteria for diagnosing dementia as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), Use the diagnostic criteria for AD from the National Institute of Neurology, Speech and Communication Disorders and Stroke - Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) or the National Institute on Aging and Alzheimer's Disease Association (NIA-AA).

Exclusion Criteria:

* Patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (Fazekas score ≥2);
* The presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, Normal facial pressure hydrocephalus);
* The presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
* There is mental and neurological retardation.
* There are other diseases that are known to cause cognitive impairment.

Primary outcomes:
measure: Comparison of refined nursing and routine nursing intervention in Alzheimer's Patients during PET/CT Imaging
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: Departments of Nuclear Medicine, Sichuan Provincial People's Hospital
state: Sichuan
Study officials:
affiliation: Sichuan Provincial People's Hospital
name: Hao Wang, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT02221830: Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
Official title: Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Preeclampsia
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2014-08-20
Enrollment: 66
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

Detailed description: The overall goal of this study is to evaluate the efficacy of postpartum 24 hour oxytocin infusion as a prevention-oriented strategy to reduce blood loss in patients with pre-eclampsia (PE) in a blinded, placebo controlled, randomized controlled trial.

Eligibility criteria: Inclusion Criteria:

1. vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age;
2. diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of \> 300mg per 24 hour period or \> 1+ on dipstick).
3. patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis)

Exclusion Criteria:

1. abnormal placentation (previa, accreta, etc)
2. antenatal hemorrhage
3. contraindication to oxytocin

Primary outcomes:
measure: Evaluation of Postpartum hematocrit
timeFrame: 24 hours postpartum
Secondary outcomes:
measure: Primary postpartum hemorrhage
timeFrame: Before discharge from hospital
measure: Estimated blood loss at delivery
timeFrame: Before discharge from hospital
measure: Postpartum blood loss
timeFrame: 24 hours postpartum
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Clinical and Translational Research Center
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Amy Hermesch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03909230: Endometrial Fluid Study in Natural Cycles: a Prospective Observational Study
Official title: Endometrial Fluid Study in Natural Cycles: a Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Fluid
Lead sponsor: Anecova SA
Sponsor class: INDUSTRY
First posted: 2019-04-09
Enrollment: 30
Sex: FEMALE
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women eligible and qualified as egg donors at IVIRMA Bilbao that meets the inclusion criteria

Brief summary: This study is designed to collect information about the characteristics of endometrial fluid at day 2 and day 4 post-ovulation in normal fertile women.

Detailed description: Implantation rates have stabilised around 35% in IVF and a current key rate limiting step is achieving successful implantation of the embryo. 1/3 of implantation failures are estimated to be caused by a problem with the receptivity of the endometrium. In recent years, several measurable parameters have been reported to assess endometrial receptivity. However, one parameter remains undescribed, the endometrial fluid viscosity.

It is generally believed that the viscosity change post ovulation is influenced by the luteal phase endocrine milieu, and it is possible that the viscosity of the endometrial fluid has an impact on implantation.

Eligibility criteria: Inclusion Criteria:

* Age: ≤ 35 years
* Women eligible and qualified for egg donation at IVIRMA Bilbao
* Proven fertile (having given birth to at least one spontaneously conceived normal child)
* Signed written consent including sharing of anonymized data

Exclusion Criteria:

* Contraindications for egg donation according to IVIRMA Bilbao guidelines

Primary outcomes:
measure: Viscosity of endometrial fluid at D2 and D4 post ovulation of the normal cycle, respectively
timeFrame: 4 days
Secondary outcomes:
measure: Plasma progesterone level
timeFrame: 4 days
measure: Plasma estradiol (E2) level
timeFrame: 4 days
measure: Endometrial thickness as measured by ultrasound
timeFrame: 4 days
Other outcomes:
Locations:
city: Leioa
country: Spain
facility: IVIRMA Bilbao
state: Vizcaya
Study officials:
References:
Clinical trial NCT01177930: Evaluation of the Health Related Quality of Life and Disease Prevalence of Children From Spain at 6-8 Years of Age Who Participated in a Qualifying Infant Formula Study at Birth
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Quality of Life
Lead sponsor: Mead Johnson Nutrition
Sponsor class: INDUSTRY
First posted: 2010-08-09
Sex: ALL
Minimum age (years): 6
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children 6 - 8 years of age

Brief summary: The purpose of this study is to evaluate the influence of the type of feeding in the first year of life on the behavior and health-related quality of life at 6-8 years of age.


Eligibility criteria: Inclusion Criteria:

* Father, mother or legal representative of a child who was included in the qualifying study
* Child 6 - 8 years of age
* Written informed consent of the father, mother or legal representative

Exclusion Criteria:

* None

Primary outcomes:
measure: Influence of the type of feeding from the first year of life on the quality of life in the same children at 6 - 8 years of age
Secondary outcomes:
Other outcomes:
Locations:
city: Las Rozas
country: Spain
facility: E-C-Bio, S.L.
state: Madrid
Study officials:
References:
Clinical trial NCT02935530: Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Official title: Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gynecologic Neoplasms
Venous Thromboembolism
Low Molecular Weight Heparin
Argatroban
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2016-10-17
Enrollment: 315
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies. Although the benefit of thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic cancers has been well documented around the world, the evidence for Chinese women is rare. The investigators designed this prospective and randomized study to assess the benefit of pharmacologic prophylaxis for patients received surgical treatment for gynecologic malignancies in China.


Eligibility criteria: Inclusion Criteria:

* Patients of ovarian cancer, cervix cancer or endometrial cancer;
* Age ≤ 70 years; female, Chinese women;
* Initial treatment is surgery;
* Laboratory tests: WBC ≥ 4×10(9)/L, NEU ≥ 2×10(9)/L, PLT ≥ 100×10(9)/L, serum bilirubin ≤ 1.5 times the upper limit of normal, transaminase ≤ 1.5 times the upper limit of normal, BUN, Cr ≤ normal
* No prior pharmacologic prophylaxis;
* Provide written informed consent.

Exclusion Criteria:

* PLT ≤ 75×10(9)/L
* Vascular injury
* History of thrombosis
* Liver and kidney dysfunction
* Concurrently participating in other clinical trials
* Unable or unwilling to sign informed consents;
* Unable or unwilling to abide by protocol.

Primary outcomes:
measure: VTE rate
timeFrame: 30-days from the date of operation
Secondary outcomes:
measure: Bleeding rate
timeFrame: 30-days from the date of operation
measure: Infection rate
timeFrame: 30-days from the date of operation
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital
state: Hubei
Study officials:
affiliation: Tongji Hospital
name: Ding Ma, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT00680225: Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Official title: Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Choroidal Melanoma
Keywords: Choroidal melanoma
Lucentis
TTT-ICG
Lead sponsor: New England Retina Associates
Sponsor class: OTHER
First posted: 2008-05-20
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 yo.
* Primary pigmented or amelanotic choroidal melanoma measurement of 16 mm or less in the largest vessel diameter and 6 mm or less in the apical height.
* Location of the tumor posterior to the equator.
* Documented growth by A/B scan.
* Risk factor for metastasis (thickness greater than 2 mm, symptoms, tumor margin at the optic disc)
* Ability to provide inform consent.
* Comply with the study assessment for the cooperation of the study.

Exclusion Criteria:

* Pregnancy or lactation.
* Premenopausal women not using adequate contraception; surgical sterilization or use of oral contraception, barrier contraception with either a condom or diaphragm or in conjunction with spermicidal gel, an IUD or contraceptive hormon implant or patch.
* Current infection or inflammation in either eye.
* Extension of tumor into the orbit.
* Retinal spread or metastatic disease.
* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
* Any known allergy to any of the components to be used in the study.
* Participation in another simultaneous medical investigation or trial.

Primary outcomes:
measure: Mean Tumor Thickness
timeFrame: 12 mo
Secondary outcomes:
measure: Visual Acuity Changes
timeFrame: 12 mo
Other outcomes:
Locations:
city: Hamden
country: United States
facility: New England Retina Associates
state: Connecticut
Study officials:
References:
Clinical trial NCT02599025: Effect of Posture and Passive Cycling on Cardiac Autonomic Control System in Children With Severe Cerebral Palsy
Official title: Effect of Posture and Passive Cycling on Cardiac Autonomic Control System in Children With Severe Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cerebral Palsy
Keywords: Cerebral palsy
passive cycling
autonomic control system
Lead sponsor: Ziv Hospital
Sponsor class: OTHER_GOV
First posted: 2015-11-06
Enrollment: 24
Sex: ALL
Minimum age (years): 6
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators will examine the immediate contribution of position and movement on the functioning of the autonomic cardiac control system.

Detailed description: Standing position is a routine therapeutic tool for improving bone density in children with cerebral palsy. The autonomous immediate response for these children is defective. In recent years it has been shown that there is an association between bone density and autonomic function .

In this paper the investigators will examine how the addition of movement to standing subjects contribute to changes in heart rate and blood pressure.

The hypothesis is that the integration of movement while standing presents a change in the autonomic response and thus may improve bone density.

Eligibility criteria: Inclusion Criteria:

* Motor ability of GMFCS IV-V

Exclusion Criteria:

* Children with hip subluxation
* On Baclofen inhaler treatment
* Heart disease
* surgical procedures

Primary outcomes:
measure: Heart rate variability
timeFrame: 10 minutes each position
measure: Blood pressure monitoring
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Ziv Medical Center, Zefat
name: Anthony Luder, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01889225: Obesity and Mortality
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity and Overweight
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2013-06-28
Enrollment: 311982
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: U.S. based prospective cohorts of adults

Brief summary: Previous analyses of the National Health and Nutrition Examination Survey have suggested that the mortality rate associated with obesity has decreased over calendar time in the U.S. population, potentially due to improvements in the medical care of obesity and its associated diseases. The primary aim of this project is to evaluate whether this reduction in the detrimental association of obesity with mortality rate over calendar time is supported by other data from U.S. prospective studies.


Eligibility criteria: Inclusion Criteria:

* U.S. based studies with at least 1500 subjects
* At least 5 years of mortality follow-up
* BMI measured or self-reported available at 2 or more separate calendar time
* Subjects varied in age at baseline

Exclusion Criteria:

* Any study that does not meet the inclusion criteria was excluded

Primary outcomes:
measure: Change in Years of Life Lost Associated with Standard BMI categories Over Calendar Time
timeFrame: Between 1960 and 2000 (up to 40 years)
Secondary outcomes:
measure: Change in Adjusted Hazard Ratio Over Calendar Time for Standard BMI Categories
timeFrame: Between 1960 and 2000 (up to 40 years)
Other outcomes:
Locations:
Study officials:
affiliation: University of Alabama at Birmingham
name: David B Allison, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01479725: Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis
Official title: A Prospective Trial Comparing the Response to Hyperbaric Oxygen Treatment in Patients With Ulcerative and Non-Ulcerative Interstitial Cystitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Interstitial Cystitis
Keywords: interstitial cystitis
Lead sponsor: William Beaumont Hospitals
Sponsor class: OTHER
Collaborators: name: William Beaumont Hospitals
First posted: 2011-11-24
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To review the results of Hyperbaric Oxygen therapy (HBOT) on the symptoms of interstitial cystitis (IC). To determine if there is greater symptom improvement in the ulcerative vs the non-ulcerative patients with interstitial cystitis.

Detailed description: There are multiple published studies outside of the United States on HBOT for treatment of interstitial cystitis. None of these studies compares ulcerative IC and non-ulcerative IC.

Eligibility criteria: Inclusion Criteria:

* Interstitial cystitis.
* Urinary frequency of at least 8 times per 24 hours period.
* Patients with ulcerative IC must have undergone previous biopsy negative for cancer.
* Patients must agree to not begin any additional treatment for IC until study completion.

Exclusion Criteria:

* Absolute or relative contraindication to hyperbaric oxygen treatment.
* Patients dependent on intermittent catheterization or indwelling catheter to empty bladder.
* Any imminent change in residence, which could compromise compliance.
* Unlikely to be compliant due to unmanaged medical or psychological problems.
* Severe debilitating concurrent medical conditions.
* A history of pelvic radiation, bladder stone, bladder cancer or cancer in situ, or urethral cancer.
* Precious bladder or neurologic surgery which has affected bladder function.
* Currently has an active urethral stone, ureteral stone or urethral diverticulum.
* Subject misses more than 10 treatments.
* Severe claustrophobia.

Primary outcomes:
measure: Global Response Assessment (GRA)
timeFrame: 3 months post treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Royal Oak
country: United States
facility: Beaumont Hospital
state: Michigan
Study officials:
affiliation: Beaumont Hospital, Royal Oak
name: Kenneth Peters, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04203225: Comparison of Two Application Techniques for LET Gel
Official title: Comparison of 2 Application Techniques for LET (Lidocaine 4%; Epinephrine 0.1%; Tetracaine 0.5%) Gel Used Prior to Simple Laceration Repair in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Lacerations
Pain, Procedural
LET
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Sponsor class: OTHER
Collaborators: name: Children's Hospital of Orange County
First posted: 2019-12-18
Enrollment: 48
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single-blinded randomized study; patients are randomized to one of two groups
Primary purpose: TREATMENT

Brief summary: Comparison of anesthetic efficacy of Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel (LET) applied three times for 10 minutes each time vs. once for 30 minutes prior to suturing simple lacerations in children aged 7-17 years.

Detailed description: Randomized single-blinded clinical trial with convenience sampling of the anesthetic efficacy of a single 30-minute application vs three 10-minute applications of Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel (LET) prior to suturing simple lacerations in children aged 7-17 years seen in the Emergency Department.

Eligibility criteria: Inclusion Criteria:

* Simple \<= 3cm lacerations requiring suturing (as decided by clinician care providers)
* Plan to suture with simple interrupted sutures

Exclusion Criteria:

* Lacerations involving the hands, feet, genitals, tongue, mucus membranes, nose, ears, or occurring over joints
* Patients whose primary language was neither English nor Spanish
* Developmentally delayed or disabled patient such that they were unable to give a pain score
* Patients requiring procedural sedation or anxiolysis with oral or intranasal midazolam

Primary outcomes:
measure: Visual Analog Scale Pain Score
timeFrame: Immediately on placement or attempt at placement of first suture
Secondary outcomes:
measure: Need for Additional Local Anesthetic
timeFrame: At any time during suturing procedure, time frame is duration of procedure, generally 10-20 minutes, less than one hour. Determined by chart review immediately after procedure completion.
Other outcomes:
Locations:
city: Orange
country: United States
facility: Children's Hospital of Orange County
state: California
city: Torrance
country: United States
facility: Harbor-UCLA Medical Center
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Kelly D Young, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Siembieda J, Heyming T, Padlipsky P, Young KD. Triple Versus Single Application of Lidocaine, Epinephrine, and Tetracaine for Laceration Repair in Children. Pediatr Emerg Care. 2022 Feb 1;38(2):e472-e474. doi: 10.1097/PEC.0000000000002631.